Patents Assigned to Gilead Biologics, Inc.
-
Patent number: 10800857Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an l=g light chain (or functional fragment thereof).Type: GrantFiled: January 10, 2019Date of Patent: October 13, 2020Assignee: Gilead Biologics, Inc.Inventors: Victoria Smith, Scott Alan McCauley
-
Patent number: 10494443Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.Type: GrantFiled: November 2, 2016Date of Patent: December 3, 2019Assignee: GILEAD BIOLOGICS, INC.Inventors: Victoria Smith, Scott Ogg, Peter Van Vlasselaer, Vivian E. Barry, Derek Marshall, Alison Kay Holzer, Hector Rodriguez, Miho Oyasu, Scott Alan McCauley, Carlos Aurelio Garcia, Donna Hiroko Tokuoka Biermann
-
Patent number: 9732156Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).Type: GrantFiled: February 28, 2013Date of Patent: August 15, 2017Assignee: Gilead Biologics, Inc.Inventors: Joanne I. Adamkewicz, Victoria Smith, Zung Thai, Michael J. Hawkins
-
Patent number: 9550836Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).Type: GrantFiled: February 29, 2012Date of Patent: January 24, 2017Assignee: Gilead Biologics, Inc.Inventors: Victoria Smith, Scott McCauley
-
Patent number: 9289447Abstract: Disclosed herein are methods and compositions for enhancing the cell-killing activity of anti-neoplastic agents by inhibiting the activity of a lysyl oxidase-type enzyme. Also disclosed are methods for screening for chemotherapeutic agents, and for molecules that enhance the activity of chemotherapeutic agents, using cells grown on an extracellular matrix.Type: GrantFiled: September 14, 2012Date of Patent: March 22, 2016Assignee: Gilead Biologics, Inc.Inventors: Victoria Smith, Alison Kay Holzer
-
Patent number: 9260532Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).Type: GrantFiled: July 3, 2013Date of Patent: February 16, 2016Assignee: Gilead Biologics, Inc.Inventors: Scott McCauley, Maria Vaysberg
-
Patent number: 9176139Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.Type: GrantFiled: May 6, 2013Date of Patent: November 3, 2015Assignee: Gilead Biologics, Inc.Inventors: Victoria Smith, Scott Ogg, Peter Van Vlasselaer, Vivian E. Barry, Derek Marshall, Alison Kay Holzer, Hector Rodriguez, Miho Oyasu, Scott Alan McCauley, Carlos Aurelio Garcia, Donna Hiroko Tokuoka Biermann
-
Patent number: 9107935Abstract: Disclosed herein are methods and compositions for enhancing the cell-killing activity of anti-neoplastic agents by inhibiting the activity of a lysyl oxidase-type enzyme. Also disclosed are methods for screening for chemotherapeutic agents, and for molecules that enhance the activity of chemotherapeutic agents, using cells grown on an extracellular matrix.Type: GrantFiled: January 5, 2010Date of Patent: August 18, 2015Assignee: Gilead Biologics, Inc.Inventors: Victoria Smith, Alison Kay Holzer
-
Publication number: 20150140580Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).Type: ApplicationFiled: February 29, 2012Publication date: May 21, 2015Applicant: Gilead Biologics, Inc.Inventors: Victoria Smith, Scott McCauley
-
Patent number: 8927700Abstract: Disclosed herein are amino acid sequences, and encoding nucleotide sequences, of isolated catalytic domains of the LOX and LOXL2 proteins from human and mouse. Methods for the preparation and use of these isolated catalytic domains are also provided.Type: GrantFiled: February 25, 2013Date of Patent: January 6, 2015Assignee: Gilead Biologics, Inc.Inventors: Scott McCauley, Victoria Smith
-
Publication number: 20140349309Abstract: The present disclosure provides innovative methodology and related compositions and kits for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysyl oxidase-like proteins, an inhibitor of LOX and an inhibitor of a LOXL, or a synergistic combination of an inhibitor of LOX or LOXL combined with other therapeutic agents. Also provided are innovative methods for selecting agents that prevent or inhibit tumor invasion, angiogenesis and metastasis, by contacting cells that are in an epithelial-mesenchymal transition (EMT) state with a candidate agent and detecting a change in the EMT state of the cells. Methods and related compositions and kits for diagnosing or monitoring various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using molecules or agents that specifically recognize processed forms of LOX or LOXL are also provided.Type: ApplicationFiled: February 4, 2014Publication date: November 27, 2014Applicant: GILEAD BIOLOGICS, INC.Inventors: Victoria SMITH, Scott OGG, Peter VAN VLASSELAER, Vivian E. BARRY, Derek MARSHALL, Alison Kay HOLZER, Hector RODRIGUEZ, Miho OYASU, Scott Alan MCCAULEY, Carlos Aurelio GARCIA, Donna Hiroko Tokuoka BIERMANN
-
Publication number: 20140302524Abstract: The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided.Type: ApplicationFiled: February 4, 2014Publication date: October 9, 2014Applicant: GILEAD BIOLOGICS, INC.Inventors: Scott Alan MCCAULEY, Hector RODRIGUEZ, Carlos Aurelio GARCIA, Victoria SMITH
-
Publication number: 20140255951Abstract: The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided.Type: ApplicationFiled: February 4, 2014Publication date: September 11, 2014Applicant: Gilead Biologics, Inc.Inventors: Scott Alan MCCAULEY, Hector RODRIGUEZ, Carlos Aurelio GARCIA, Victoria SMITH
-
Publication number: 20140186340Abstract: Disclosed herein are methods and compositions for increasing perfusion, reducing hypoxia, reducing permeability and increasing the integrity of vasculature; e.g., in a tumor. The compositions include inhibitors of the LOXL2 enzyme. In certain of the methods, a LOXL2 inhibitor is used in combination with, and facilitates the therapeutic activity of, an anti-neoplastic agent.Type: ApplicationFiled: April 6, 2012Publication date: July 3, 2014Applicant: GILEAD BIOLOGICS, INC.Inventors: Derek Marshall, Rhyannon Spangler, Victoria Smith
-
Publication number: 20140128284Abstract: Provided are methodology, compositions and kits to prevent and treat diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using processed lysyl oxidase or lysyl oxidase-like protein inhibitors, LOX inhibitors and LOXL inhibitors, or synergistic combinations of such inhibitors with therapeutic agents. Provided are methods for selecting tumor invasion, angiogenesis and metastasis inhibiting agents, by contacting cells in EMT states with candidate agents and detecting changes in such states; and methods, compositions, and kits for diagnosing or monitoring diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using molecules or agents specifically recognizing processed LOX or LOXL. Provided are methods, compositions, medical devices, systems and kits for preventing or treating diseases and conditions associated with fibrosis, including pathological cardiovascular conditions and diseases, e.g.Type: ApplicationFiled: December 19, 2013Publication date: May 8, 2014Applicant: Gilead Biologics, Inc.Inventors: Victoria Smith, Scott OGG, Peter VAN VLASSELAER, Vivian E. BARRY, Derek MARSHALL, Alison Kay HOLZER, Hector RODRIGUEZ, Miho OYASU, Scott Alan MCCAULEY, Carlos Aurelio GARCIA, Donna Hiroko Tokuoka BIERMANN
-
Patent number: 8679485Abstract: The present disclosure provides methodology and compositions for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysyl oxidase-like proteins, an inhibitor of LOX or LOXL, or a synergistic combination thereof combined with other therapeutic agents. Methods and compositions for diagnosing or monitoring various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, are also provided. Also provided herein are methods and related compositions, medical devices, systems and kits for preventing or treating various diseases and conditions associated with fibrosis with compositions comprising inhibitors of LOX or LOXL.Type: GrantFiled: August 1, 2008Date of Patent: March 25, 2014Assignee: Gilead Biologics, Inc.Inventors: Victoria Smith, Scott Ogg, Peter Van Vlasselaer, Vivian E. Barry, Derek Marshall, Alison Kay Holzer, Hector Rodriguez, Miho Oyasu, Scott Alan McCauley, Carlos Aurelio Garcia, Donna Hiroko Tokuoka Biermann
-
Patent number: 8680246Abstract: The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided.Type: GrantFiled: February 4, 2011Date of Patent: March 25, 2014Assignee: Gilead Biologics, Inc.Inventors: Scott Alan McCauley, Hector Rodriguez, Carlos Aurelio Garcia, Victoria Smith
-
Publication number: 20140079707Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.Type: ApplicationFiled: May 6, 2013Publication date: March 20, 2014Applicant: GILEAD BIOLOGICS, INC.Inventors: Victoria SMITH, Scott OGG, Peter VAN VLASSELAER, Vivian E. BARRY, Derek MARSHALL, Alison Kay HOLZER, Hector RODRIGUEZ, Miho OYASU, Scott Alan MCCAULEY, Carlos Aurelio GARCIA, Donna Hiroko Tokuoka BIERMANN
-
Patent number: 8658167Abstract: Provided are methodology, compositions and kits to prevent and treat diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using processed lysyl oxidase or lysyl oxidase-like protein inhibitors, LOX inhibitors and LOXL inhibitors, or synergistic combinations of such inhibitors with therapeutic agents. Provided are methods for selecting tumor invasion, angiogenesis and metastasis inhibiting agents, by contacting cells in EMT states with candidate agents and detecting changes in such states; and methods, compositions, and kits for diagnosing or monitoring diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using molecules or agents specifically recognizing processed LOX or LOXL. Provided are methods, compositions, medical devices, systems and kits for preventing or treating diseases and conditions associated with fibrosis, including pathological cardiovascular conditions and diseases, e.g.Type: GrantFiled: December 6, 2012Date of Patent: February 25, 2014Assignee: Gilead Biologics, Inc.Inventors: Victoria Smith, Scott Ogg, Peter Van Vlasselaer, Vivian E. Barry, Derek Marshall, Alison Kay Holzer, Hector Rodriguez, Miho Oyasu, Scott Alan McCauley, Carlos Aurelio Garcia, Donna Hiroko Tokuoka Biermann
-
Publication number: 20130324705Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.Type: ApplicationFiled: May 6, 2013Publication date: December 5, 2013Applicant: GILEAD BIOLOGICS, INC.Inventors: Victoria SMITH, Scott OGG, Peter VAN VLASSELAER, Vivian E. BARRY, Derek MARSHALL, Alison Kay HOLZER, Hector RODRIGUEZ, Miho OYASU, Scott Alan MCCAULEY, Carlos Aurelio GARCIA, Donna Hiroko Tokuoka BIERMANN